AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33356004 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg furosemide
Number of subjects: 0
Study 34418858 — intervention group
Group type: EXPERIMENTAL
Intervention: Triceps surae stretching (4 × 60 seconds)
Number of subjects: 19
Study 34418858 — intervention group
Group type: COMPARATOR
Intervention: Sham group (forearm stretching)
Number of subjects: 19
Study 34418858 — intervention group
Group type: COMPARATOR
Intervention: Control group (age-matched healthy elderly, no stretching treatment)
Number of subjects: 19
Study 32444619 — intervention group
Group type: EXPERIMENTAL
Intervention: Compassionate coach (CC) image
Number of subjects: 200
Study 32444619 — intervention group
Group type: EXPERIMENTAL
Intervention: Loving kindness meditation (LKM)
Number of subjects: 200
Study 34423693 — intervention group
Group type: EXPERIMENTAL
Intervention: Client-Centered (CC) intervention with telerehabilitation (TR) method
Number of subjects: 38
Study 32087340 — intervention group
Group type: EXPERIMENTAL
Intervention: Compendium of implementation strategies to add or enhance smoking cessation services during lung screening
Number of subjects: 26
Study 32087340 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 26
Study 34813467 — intervention group
Group type: EXPERIMENTAL
Intervention: eM-KOFL
Number of subjects: 0
Study 34813467 — intervention group
Group type: EXPERIMENTAL
Intervention: pM-KOFL
Number of subjects: 0
Study 34813467 — intervention group
Group type: EXPERIMENTAL
Intervention: vM-KOFL
Number of subjects: 0
Study 34813467 — intervention group
Group type: COMPARATOR
Intervention: S-KOFL
Number of subjects: 0
Study 32977254 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mL low‐dose anthocyanin (5 mg/100 g) QGP nectar
Number of subjects: 28
Study 32977254 — intervention group
Group type: COMPARATOR
Intervention: Raspberry cordial (control)
Number of subjects: 28
Study 34331348 — intervention group
Group type: EXPERIMENTAL
Intervention: Fedratinib 400 mg daily
Number of subjects: 0
Study 34331348 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32365355 — intervention group
Group type: EXPERIMENTAL
Intervention: L-thyroxine
Number of subjects: 638
Study 32365355 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 638
Study 34044816 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding Heritage and Pride program (BHP)
Number of subjects: 0
Study 32011655 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacosamide at a concentration of 30 μM
Number of subjects: 0
Study 35199262 — intervention group
Group type: EXPERIMENTAL
Intervention: HIE plus CTI
Number of subjects: 347
Study 35199262 — intervention group
Group type: COMPARATOR
Intervention: HIE alone
Number of subjects: 347
Study 36056636 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lipid lowering therapy (rosuvastatin 40 mg + ezetimibe 10 mg daily)
Number of subjects: 104
Study 36056636 — intervention group
Group type: COMPARATOR
Intervention: Standard lipid lowering therapy (atorvastatin 40 mg daily)
Number of subjects: 104
Study 33832531 — intervention group
Group type: EXPERIMENTAL
Intervention: Gap Balancing (GB) technique
Number of subjects: 96
Study 33832531 — intervention group
Group type: COMPARATOR
Intervention: Measured Resection (MR) technique
Number of subjects: 96
Study 36198032 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person visits
Number of subjects: 1769
Study 36198032 — intervention group
Group type: COMPARATOR
Intervention: Telemedicine visits
Number of subjects: 1769
Study 33617333 — intervention group
Group type: EXPERIMENTAL
Intervention: Holmium laser enucleation of the prostate using MOSES technology
Number of subjects: 60
Study 33617333 — intervention group
Group type: COMPARATOR
Intervention: Holmium laser enucleation of the prostate
Number of subjects: 60
Study 32819429 — intervention group
Group type: EXPERIMENTAL
Intervention: CCTA/CT-FFR strategy (group A)
Number of subjects: 1216
Study 32819429 — intervention group
Group type: COMPARATOR
Intervention: Usual care (group B)
Number of subjects: 1216
Study 33740564 — intervention group
Group type: EXPERIMENTAL
Intervention: Brainstem auditory evoked responses (BAER)
Number of subjects: 24
Study 33740564 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone conduction (BC)
Number of subjects: 24
Study 33740564 — intervention group
Group type: EXPERIMENTAL
Intervention: Brainstem auditory evoked responses (BAER) and Bone conduction (BC)
Number of subjects: 24
Study 33196464 — intervention group
Group type: EXPERIMENTAL
Intervention: MVT‐602 (0.01 and 0.03 nmol/kg)
Number of subjects: 21
Study 33196464 — intervention group
Group type: EXPERIMENTAL
Intervention: MVT‐602
Number of subjects: 21
Study 33196464 — intervention group
Group type: COMPARATOR
Intervention: KP54 (9.6 nmol/kg)
Number of subjects: 21
Study 33403688 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin-to-skin contact with father
Number of subjects: 95
Study 33403688 — intervention group
Group type: COMPARATOR
Intervention: Cot
Number of subjects: 95
Study 33403688 — intervention group
Group type: COMPARATOR
Intervention: Fathers' arms
Number of subjects: 95
Study 36335639 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose trivalent influenza vaccine
Number of subjects: 5210
Study 32914237 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 180
Study 32914237 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy
Number of subjects: 180
Study 32914237 — intervention group
Group type: EXPERIMENTAL
Intervention: R0 resected tumors
Number of subjects: 180
Study 32916855 — intervention group
Group type: EXPERIMENTAL
Intervention: Blues Program indicated prevention intervention
Number of subjects: 220
Study 32916855 — intervention group
Group type: COMPARATOR
Intervention: Group membership
Number of subjects: 220
Study 35331539 — intervention group
Group type: EXPERIMENTAL
Intervention: Paleolithic‐based low‐carbohydrate diet with calorie‐counting method (PLCD‐CC)
Number of subjects: 80
Study 35331539 — intervention group
Group type: EXPERIMENTAL
Intervention: Paleolithic‐based low‐carbohydrate diet with portion‐control method (PLCD‐PC)
Number of subjects: 80
Study 35331539 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate‐carbohydrate diet with calorie‐counting method (MCD‐CC)
Number of subjects: 80
Study 35331539 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate‐carbohydrate diet with portion‐control method (MCD‐PC)
Number of subjects: 80
Study 33293185 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 10 µg
Number of subjects: 100
Study 33293185 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 100
Study 34101892 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivoceranib 201 mg with food
Number of subjects: 44
Study 34101892 — intervention group
Group type: COMPARATOR
Intervention: Rivoceranib 201 mg without food
Number of subjects: 44
Study 34101892 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivoceranib 81 mg with food
Number of subjects: 44
Study 34101892 — intervention group
Group type: COMPARATOR
Intervention: Rivoceranib 81 mg without food
Number of subjects: 44
Study 33146345 — intervention group
Group type: EXPERIMENTAL
Intervention: CBD 300 mg/day
Number of subjects: 31
Study 33146345 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 36229671 — intervention group
Group type: EXPERIMENTAL
Intervention: ePRO web-app (ABATON RA)
Number of subjects: 10
Study 33402102 — intervention group
Group type: EXPERIMENTAL
Intervention: SOX regimen (oxaliplatin combined with S-1) for six cycles (three cycles followed by another three cycles for group A)
Number of subjects: 524
Study 33402102 — intervention group
Group type: COMPARATOR
Intervention: SOX regimen (oxaliplatin combined with S-1) for three cycles (group B)
Number of subjects: 524
Study 33402102 — intervention group
Group type: EXPERIMENTAL
Intervention: SOX regimen (oxaliplatin combined with S-1) for six cycles (group A)
Number of subjects: 524
Study 32510130 — intervention group
Group type: EXPERIMENTAL
Intervention: NK3Ra (MLE4901) 40 mg orally twice a day for 7 days
Number of subjects: 15
Study 32510130 — intervention group
Group type: EXPERIMENTAL
Intervention: Kisspeptin-10 (4 µg/kg/h i.v.) after NK3Ra treatment
Number of subjects: 15
Study 32510130 — intervention group
Group type: COMPARATOR
Intervention: Kisspeptin-10 (4 µg/kg/h i.v.) without NK3Ra treatment
Number of subjects: 15
Study 34591356 — intervention group
Group type: EXPERIMENTAL
Intervention: sacubitril/valsartan 97/103 mg bid (n=103)
Number of subjects: 201
Study 34591356 — intervention group
Group type: COMPARATOR
Intervention: enalapril 10 mg bid (n=98)
Number of subjects: 201
Study 34591356 — intervention group
Group type: EXPERIMENTAL
Intervention: sacubitril/valsartan 97/103 mg bid
Number of subjects: 201
Study 34591356 — intervention group
Group type: COMPARATOR
Intervention: enalapril 10 mg bid
Number of subjects: 201
Study 33033091 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled regional analgesia (PCRA) - ultrasound-guided subgluteal sciatic catheterisation, continuous infusion of 0.2% ropivacaine (15 mL loading dose, 8 mL/hour background, 6 mL patient-controlled bolus)
Number of subjects: 52
Study 33033091 — intervention group
Group type: COMPARATOR
Intervention: Patient-controlled intravenous analgesia (PCIA) - morphine in boluses of 1 mg as needed, background infusion at 1 mg/hour
Number of subjects: 52
Study 33033091 — intervention group
Group type: EXPERIMENTAL
Intervention: PCRA
Number of subjects: 52
Study 33033091 — intervention group
Group type: COMPARATOR
Intervention: PCIA
Number of subjects: 52
Study 36364907 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg Irvingia gabonensis (IG) extract
Number of subjects: 0
Study 36364907 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 0
Study 32565344 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACYW-TT
Number of subjects: 3344
Study 32565344 — intervention group
Group type: COMPARATOR
Intervention: MCV4-DT
Number of subjects: 3344
Study 32565344 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACYW-TT and MCV4-DT
Number of subjects: 3344
Study 35581610 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral Thinking Method (LTM)
Number of subjects: 272
Study 35581610 — intervention group
Group type: COMPARATOR
Intervention: Traditional Didactic Method
Number of subjects: 272
Study 33693481 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate dose alcohol
Number of subjects: 0
Study 33693481 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32179922 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalational methoxyflurane (Penthrox®)
Number of subjects: 343
Study 32179922 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular tramadol
Number of subjects: 343
Study 36409480 — intervention group
Group type: COMPARATOR
Intervention: Irrigation fluid at room temperature (RT group)
Number of subjects: 541
Study 36409480 — intervention group
Group type: EXPERIMENTAL
Intervention: Irrigation fluid at body temperature (BT group)
Number of subjects: 541
Study 36409480 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality, health-related quality of life, and complication frequency
Number of subjects: 541
Study 33462622 — intervention group
Group type: EXPERIMENTAL
Intervention: Bloodletting (3 scheduled bloodlettings after a 3-month run-in period with 35 μg ethinylestradiol plus 2 mg cyproterone acetate)
Number of subjects: 33
Study 33462622 — intervention group
Group type: COMPARATOR
Intervention: Observation (after a 3-month run-in period with 35 μg ethinylestradiol plus 2 mg cyproterone acetate)
Number of subjects: 33
Study 33462622 — intervention group
Group type: EXPERIMENTAL
Intervention: Bloodletting
Number of subjects: 33
Study 33990812 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitrification solutions with sucrose (VS1)
Number of subjects: 0
Study 33990812 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitrification solutions without sucrose (VS2 and VS4)
Number of subjects: 0
Study 33990812 — intervention group
Group type: EXPERIMENTAL
Intervention: Warming solution containing trehalose
Number of subjects: 0
Study 33990812 — intervention group
Group type: EXPERIMENTAL
Intervention: Warming solution containing sucrose
Number of subjects: 0
Study 33990812 — intervention group
Group type: COMPARATOR
Intervention: Control group (directly subjected to IVM)
Number of subjects: 0
Study 33438761 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental treatment
Number of subjects: 0
Study 33438761 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 33798525 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal ablation of the defect margin after endoscopic mucosal resection (EMR‐T)
Number of subjects: 1049
Study 32787783 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic methoxamine infusion at 1 μg/kg/min (Group M1)
Number of subjects: 80
Study 32787783 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic methoxamine infusion at 2 μg/kg/min (Group M2)
Number of subjects: 80
Study 32787783 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic methoxamine infusion at 3 μg/kg/min (Group M3)
Number of subjects: 80
Study 32787783 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic methoxamine infusion at 4 μg/kg/min (Group M4)
Number of subjects: 80
Study 32787783 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic methoxamine infusion (all groups)
Number of subjects: 80
Study 33894009 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture in addition to usual care for three days (acupuncture points: Pericardium‐6, Stomach‐36, Liver‐3, Yin Tang)
Number of subjects: 112
Study 33894009 — intervention group
Group type: COMPARATOR
Intervention: Usual care only (control group)
Number of subjects: 112
Study 33894009 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture in addition to usual care
Number of subjects: 112
Study 33605586 — intervention group
Group type: EXPERIMENTAL
Intervention: nCRT followed by surgery
Number of subjects: 0
Study 33538444 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-aided intraoperative navigation (Ci-Navi)
Number of subjects: 52
Study 33538444 — intervention group
Group type: COMPARATOR
Intervention: Conventional intraoperative navigation methods
Number of subjects: 52
Study 32664033 — intervention group
Group type: COMPARATOR
Intervention: Placebo expectation group (expectation to receive a placebo)
Number of subjects: 94
Study 32664033 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug expectation group (expectation to receive a fast-operating antidepressant)
Number of subjects: 94
Study 32664033 — intervention group
Group type: COMPARATOR
Intervention: No treatment group (no expectation, no placebo)
Number of subjects: 94
Study 35157756 — intervention group
Group type: EXPERIMENTAL
Intervention: Dural puncture epidural
Number of subjects: 141
Study 35157756 — intervention group
Group type: COMPARATOR
Intervention: Standard epidural
Number of subjects: 141
Study 32331038 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided-care (combinatorial pharmacogenomic testing)
Number of subjects: 1298
Study 32331038 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided-care (combinatorial pharmacogenomic testing) with gene-drug interactions
Number of subjects: 1298
Study 32331038 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 1298
Study 35114727 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational family intervention (PFI)
Number of subjects: 137
Study 35114727 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control)
Number of subjects: 137
Study 32918892 — intervention group
Group type: EXPERIMENTAL
Intervention: FF/UMEC/VI 100/62.5/25 μg
Number of subjects: 2439
Study 32918892 — intervention group
Group type: EXPERIMENTAL
Intervention: FF/UMEC/VI 200/62.5/25 μg
Number of subjects: 2439
Study 32918892 — intervention group
Group type: EXPERIMENTAL
Intervention: FF/UMEC/VI 100/31.25/25 μg
Number of subjects: 2439
Study 32918892 — intervention group
Group type: EXPERIMENTAL
Intervention: FF/UMEC/VI 200/31.25/25 μg
Number of subjects: 2439
Study 32918892 — intervention group
Group type: COMPARATOR
Intervention: FF/VI 100/25 μg
Number of subjects: 2439
Study 32918892 — intervention group
Group type: COMPARATOR
Intervention: FF/VI 200/25 μg
Number of subjects: 2439
Study 32918892 — intervention group
Group type: EXPERIMENTAL
Intervention: All pooled treatment groups
Number of subjects: 2439
Study 32918892 — intervention group
Group type: EXPERIMENTAL
Intervention: FF/UMEC 62.5 μg/VI
Number of subjects: 2439
Study 32918892 — intervention group
Group type: EXPERIMENTAL
Intervention: FF/UMEC 31.25 μg/VI
Number of subjects: 2439
Study 32918892 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 2439
Study 35914695 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozonated Water (OW)
Number of subjects: 50
Study 35914695 — intervention group
Group type: EXPERIMENTAL
Intervention: KTP Laser
Number of subjects: 50
Study 35914695 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine (CHX)
Number of subjects: 50
Study 35914695 — intervention group
Group type: EXPERIMENTAL
Intervention: Rose Bengal Photosensitizer (RBP)
Number of subjects: 50
Study 35914695 — intervention group
Group type: EXPERIMENTAL
Intervention: Er, YAG Laser
Number of subjects: 50
Study 32867803 — intervention group
Group type: EXPERIMENTAL
Intervention: Late parenteral nutrition (late-PN)
Number of subjects: 96
Study 35305317 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA-NP+M1 (1·5 × 10^8 plaque-forming units)
Number of subjects: 2152
Study 35305317 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 2152
Study 35305317 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA-NP+M1
Number of subjects: 2152
Study 35305317 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2152
Study 35051685 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo presented as propranolol
Number of subjects: 60
Study 35051685 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control group
Number of subjects: 60
Study 35051685 — intervention group
Group type: COMPARATOR
Intervention: Placebo (generic)
Number of subjects: 60
Study 35657468 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine visits for contraception (phone or video)
Number of subjects: 1414
Study 35657468 — intervention group
Group type: EXPERIMENTAL
Intervention: Food insecurity
Number of subjects: 1414
Study 35657468 — intervention group
Group type: EXPERIMENTAL
Intervention: Housing insecurity
Number of subjects: 1414
Study 33924871 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted arachidonic acid (% of total fatty acids increase)
Number of subjects: 0
Study 33924871 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted arachidonic acid
Number of subjects: 0
Study 32877910 — intervention group
Group type: EXPERIMENTAL
Intervention: Imaginal retraining (self-help manual)
Number of subjects: 345
Study 32877910 — intervention group
Group type: COMPARATOR
Intervention: Control group (active or wait-list)
Number of subjects: 345
Study 616063481 — intervention group
Group type: EXPERIMENTAL
Intervention: T+CEF (3 cycles of docetaxel followed by 3 cycles of CEF)
Number of subjects: 1014
Study 616063481 — intervention group
Group type: EXPERIMENTAL
Intervention: TX+CEX (docetaxel plus capecitabine followed by 3 cycles of cyclophosphamide, epirubicin and capecitabine)
Number of subjects: 1014
Study 616063481 — intervention group
Group type: COMPARATOR
Intervention: V+CEF (3 cycles of weekly vinorelbine followed by 3 cycles of CEF)
Number of subjects: 1014
Study 616063481 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant trastuzumab (for HER2+ BC)
Number of subjects: 1014
Study 35581629 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg/day for 6 weeks
Number of subjects: 55
Study 35581629 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 weeks
Number of subjects: 55
Study 33522512 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mA tDCS during virtual reality exposure
Number of subjects: 0
Study 33522512 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation during virtual reality exposure
Number of subjects: 0
Study 35557256 — intervention group
Group type: EXPERIMENTAL
Intervention: tVNSab (pulse width = 200 ms; pulse frequency = 30 Hz)
Number of subjects: 7
Study 35557256 — intervention group
Group type: COMPARATOR
Intervention: SHAM (time-control visit with no current applied)
Number of subjects: 7
Study 33847156 — intervention group
Group type: EXPERIMENTAL
Intervention: Convolutional Neural Network (CNN) for kidney and tumor segmentation on single-phase CT scans
Number of subjects: 319
Study 33571743 — intervention group
Group type: EXPERIMENTAL
Intervention: Access control measures on workstations
Number of subjects: 773
Study 33571743 — intervention group
Group type: COMPARATOR
Intervention: Regional and organizational level privacy regulations
Number of subjects: 773
Study 33571743 — intervention group
Group type: EXPERIMENTAL
Intervention: Single hospital-wide EMR
Number of subjects: 773
Study 32562395 — intervention group
Group type: EXPERIMENTAL
Intervention: Ringer Lactate (RL)
Number of subjects: 72
Study 32562395 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal Saline (NS)
Number of subjects: 72
Study 35237953 — intervention group
Group type: EXPERIMENTAL
Intervention: HT‐ESPB catheter
Number of subjects: 30
Study 35237953 — intervention group
Group type: COMPARATOR
Intervention: Interscalene catheter
Number of subjects: 30
Study 35237953 — intervention group
Group type: EXPERIMENTAL
Intervention: HT‐ESPB
Number of subjects: 30
Study 35237953 — intervention group
Group type: COMPARATOR
Intervention: Interscalene
Number of subjects: 30
Study 32081517 — intervention group
Group type: EXPERIMENTAL
Intervention: NefroPortatil mobile application
Number of subjects: 52
Study 33210997 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial preparation (sildenafil tablet 20 mg)
Number of subjects: 20
Study 33210997 — intervention group
Group type: COMPARATOR
Intervention: Reference preparation (sildenafil tablet 20 mg)
Number of subjects: 20
Study 36086930 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone OMP (5 mg/week)
Number of subjects: 30
Study 36086930 — intervention group
Group type: COMPARATOR
Intervention: DPCP contact sensitization
Number of subjects: 30
Study 34085830 — intervention group
Group type: EXPERIMENTAL
Intervention: Particle Swarm Optimization (PSO)
Number of subjects: 0
Study 34085830 — intervention group
Group type: COMPARATOR
Intervention: Genetic Algorithm (GA)
Number of subjects: 0
Study 32185595 — intervention group
Group type: EXPERIMENTAL
Intervention: CFα late‐start: CFα on day 4 + GnRH antagonist from day 8 + recFSH from day 11 (when needed)
Number of subjects: 113